

Regulatory Considerations in Supplemental BLA Submission for the Addition of Drug-Linker Manufacturing Sites in Antibody-Drug Conjugates

Thota Sathvika*, Cheeli Rishitha**, Dr. Shailaja Pashikanti***, G. Sneha Latha****

*(Drug Regulatory Affairs, A.U College of pharmaceutical sciences, Visakhapatnam

Email: sathvikathota36@gmail.com)

** (Drug Regulatory Affairs, A.U College of pharmaceutical sciences, Visakhapatnam

Email : sathvikathota36@gmail.com)

*** (Department of Regulatory Affairs, Andhra University, Visakhapatnam, Andhra Pradesh, India)

**** (Department of Regulatory Affairs, Andhra University, Visakhapatnam, Andhra Pradesh, India)

Abstract:

Antibody-drug conjugates (ADCs) are complex biotherapeutics built from a monoclonal antibody, a cytotoxic payload, and a chemical linker, and their growing clinical use often pushes manufacturers to expand production capacity once a product is approved. Adding a new drug-linker manufacturing site is one of the more common ways this expansion happens, but in the United States it triggers a Supplemental Biologics License Application (sBLA), usually filed as a Prior Approval Supplement. Because the drug-linker has such a direct bearing on product stability, safety, and clinical performance, regulators expect sponsors to show, with solid evidence, that material from the new site is comparable to material from the original one. This review walks through what that evidence typically involves — CMC data, analytical comparability, process validation, stability studies, and inspection readiness — and closes with a case study that illustrates how these requirements play out in practice.

Keywords — Antibody–drug conjugates, Supplemental BLA, Prior Approval Supplement, Drug-linker, Manufacturing site addition, Comparability, CMC, Regulatory affairs.

I. INTRODUCTION

Antibody-drug conjugates represent one of the more sophisticated classes of targeted cancer therapy available today. By pairing the specificity of a monoclonal antibody with a highly potent small-molecule payload through a purpose-built chemical linker, ADCs manage to deliver cytotoxic activity more selectively than conventional chemotherapy, which improves their therapeutic index (4,9). Because the antibody component is biologic in nature and the conjugation chemistry adds another layer of complexity, ADCs are regulated as biologics and reach the market through a Biologics License Application (10). This classification means that manufacturing control, process consistency, and lifecycle management receive close regulatory attention throughout a product's life.

Producing an ADC is rarely a single-site operation. Antibody production, payload synthesis,

linker manufacturing, and conjugation are frequently split across different facilities, and the drug-linker step in particular has an outsized influence on conjugation efficiency, drug-to-antibody ratio (DAR), impurity formation, and overall product stability (4). As a product moves further into commercialization, sponsors often need to bring a second or third drug-linker site online, either to keep up with demand or to reduce supply chain risk. Because these changes can affect quality, safety, or efficacy, they are treated as significant and generally require a supplemental Biologics License Application (2). Understanding what regulators expect from these site-addition submissions matters a great deal for sponsors trying to avoid supply interruptions while still meeting approval timelines. Figure 1 shows the basic structural components of an ADC — the monoclonal antibody, the chemical linker, and the cytotoxic payload.




Fig. 1. Structure of an antibody-drug conjugate (ADC), showing the antibody, cleavable linker, and cytotoxic payload.

II. REGULATORY FRAMEWORK FOR POST-APPROVAL CHANGES

Regulators classify post-approval changes to licensed biologics according to how much they could affect product quality, safety, or efficacy (2). It's well understood that manufacturing processes for complex biologics evolve over time — through scale-up, technology transfer, or simply shifting supply chains (8) — so a structured framework exists to make sure those changes don't compromise the product that was originally approved. Adding a new site for a critical starting material or intermediate usually counts as a major change, since any variability introduced at that stage can carry through downstream and show up in the final product.

For ADCs specifically, the drug-linker is treated as a particularly sensitive component. It shapes conjugation efficiency, how stable the molecule remains in systemic circulation, how the payload is released, and ultimately the therapeutic index. Even small differences in synthesis conditions, raw materials, or purification at a new site can shift impurity profiles or physicochemical properties in ways that affect clinical performance. That's why regulators insist on a thorough evaluation before allowing such a change.

In the United States, adding a new manufacturing site for a critical component typically calls for a Prior Approval Supplement (PAS) filed under an sBLA, per 21 CFR 601.12

(2). Sponsors need to submit extensive CMC data showing that the change doesn't compromise the product's identity, strength, quality, purity, or potency, and they can't distribute material from the new site until approval is granted. A pre-approval inspection of the facility is common practice, confirming that current Good Manufacturing Practice (cGMP) requirements are being met (5,11).

Other regions follow broadly similar paths. In the European Union, this kind of change is usually classified as a Type II variation, requiring formal assessment and approval before implementation (3). Many other jurisdictions apply comparable major-variation procedures aligned with ICH guidelines, notably ICH Q5E on comparability of biotechnological products after manufacturing changes (1). The terminology and procedural detail differ from one agency to another, but the underlying expectation is consistent everywhere: sponsors must demonstrate that pre-change and post-change material are highly comparable, and that the product's benefit-risk profile hasn't shifted.

III. CRITICAL ROLE OF THE DRUG LINKER IN ADC PERFORMANCE

The drug linker does a lot of work in determining how an ADC performs. It governs payload stability while the molecule circulates, how efficiently conjugation to the antibody occurs, and how the cytotoxic agent is released once it reaches the target cell. It also shapes DAR, pharmacokinetics, and, ultimately, the therapeutic index. Because ADC payloads are so potent, even trace impurities or degradation products can carry real safety implications (4,9).

Changes to the synthesis route, raw materials, scale, or process conditions at a new site can alter stereochemistry, leave behind different residual reagents, or shift impurity profiles — any of which can affect how the linker behaves during conjugation, how stable the final conjugate is, and how consistent batches are with one another. Given all this, regulators treat the drug linker as a critical quality component and expect thorough characterization, validated analytical testing, and a

full comparability assessment before material from a new facility is cleared for commercial use (1).

IV. CMC REQUIREMENTS FOR SITE ADDITION

The Chemistry, Manufacturing, and Controls (CMC) section is really the backbone of an sBLA for a major manufacturing change — it's where the sponsor makes the case that product quality won't change once the new site comes online. Regulators comb through this data specifically to confirm that identity, purity, potency, and safety remain unaffected.

A. Facility and GMP Compliance

Sponsors are expected to describe the new facility in detail: its layout, the containment systems used for highly potent compounds, environmental controls, and how it complies with cGMP (5,11). Equipment qualification, utility systems, and quality management practices also need to be documented. Because drug-linker manufacturing often involves cytotoxic substances, regulators pay particularly close attention to personnel training, occupational safety, cross-contamination controls, and waste management. A pre-approval inspection is often used to confirm the site is genuinely ready for production (5).

B. Manufacturing Process Description

Sponsors need to provide a detailed account of how the drug-linker is synthesized at the new site — raw materials, reaction conditions, purification steps, and process controls all need to be spelled out. Any differences from the previously approved process should be flagged, scientifically justified, and backed by a risk assessment. A robust control strategy, including defined critical process parameters, in-process controls, and acceptance criteria, helps ensure the site consistently produces material that meets specification.

C. Analytical Methods and Method Transfer

Validated analytical methods are needed to assess identity, purity, potency, and impurity

profiles of the drug-linker material. Where testing moves to the new facility, method transfer studies have to show that the receiving lab can match the performance of the original site — typically covering accuracy, precision, specificity, and robustness. Regulators also tend to encourage orthogonal analytical techniques, since they add complementary evidence and strengthen confidence in the comparability conclusions. Table 1 summarizes the key CMC information regulators generally expect for a drug-linker site addition.

TABLE I. KEY CMC INFORMATION EXPECTED FOR A DRUG-LINKER SITE ADDITION

CMC Element	Key Information Required	Regulatory Purpose
Facility details	Layout, containment systems, GMP compliance	Ensure safe handling of highly potent compounds
Manufacturing process	Synthesis steps, process controls, parameters	Assess reproducibility and consistency
Equipment qualification	IQ/OQ/PQ documentation	Verify reliability of manufacturing equipment
Analytical methods	Method validation data	Ensure accurate quality assessment
Method transfer	Transfer protocol and results	Demonstrate equivalent testing capability
Control strategy	Critical process parameters and acceptance criteria	Maintain consistent product quality

V. ANALYTICAL COMPARABILITY ASSESSMENT

Comparability studies sit at the center of how regulators evaluate post-approval manufacturing changes. Sponsors have to show that drug-linker material from the new site closely matches material from the original one, so that the change has no bearing on final product quality. This typically involves structural confirmation, impurity profiling, residual solvent analysis, and stability-indicating assays performed with validated methods. Regulators usually expect multiple representative batches to be evaluated, often supported by statistical analysis to substantiate a claim of equivalence — all of which helps confirm that whatever variability the

new site introduces stays within acceptable bounds (1).

VI. EVALUATION OF THE FINAL ADC PRODUCT

Since the drug-linker becomes part of the finished conjugate, regulators also look at how it affects the final ADC product, not just the intermediate itself. This usually means examining DAR distribution, aggregation levels, potency, binding activity, and physicochemical stability, and sometimes comparative pharmacokinetic or functional studies as well. If any meaningful differences turn up, regulators may ask for additional nonclinical or clinical bridging studies before they're satisfied that safety and efficacy haven't been affected.

VII. PROCESS VALIDATION AND SCALE-UP CONSIDERATIONS

Process validation is how a sponsor demonstrates that the new site can reliably produce material meeting predefined specifications. This usually means data from several validation batches, along with process capability analysis and confirmation that the control strategy holds up in practice. Critical process parameters that could influence impurity formation or stability get particular scrutiny, and if the new site operates at a different scale, sponsors need to justify why scale-up doesn't change reaction kinetics, yield, or critical quality attributes. Solid validation data goes a long way toward reassuring regulators that long-term production will stay reliable.

VIII. STABILITY DATA REQUIREMENTS

Stability studies confirm that drug-linker material from the new site holds up over the proposed shelf life. Sponsors typically provide both accelerated and long-term stability data under appropriate storage conditions, along with an evaluation of degradation pathways, impurity growth, and retest periods. Where the full long-term dataset isn't available yet, regulators may accept interim data paired with a commitment to keep the stability program running after approval

(6). This helps ensure the change won't compromise how the product holds up during storage and distribution. Table 2 summarizes the analytical techniques commonly used in these comparability studies.

TABLE II. ANALYTICAL TECHNIQUES USED IN COMPARABILITY STUDIES

Attribute	Analytical Techniques	Purpose
Identity	Spectroscopy, LC-MS	Confirm chemical structure
Purity	HPLC/UPLC	Detect impurities
Residual solvents	Gas chromatography	Safety evaluation
Impurity profile	LC-MS, NMR	Identify process-related impurities
Biological activity	Functional assays	Confirm potency
Stability	Degradation studies	Establish shelf life
Batch consistency	Statistical analysis	Demonstrate equivalence

IX. REGULATORY REVIEW AND INSPECTION

Regulatory agencies review sBLA submissions using a risk-based approach, weighing whether the proposed change could touch on product quality, safety, or efficacy. Reviewers look closely at how solid the comparability data is, how robust the manufacturing controls are, and whether the facility can safely handle highly potent materials. Pre-approval inspections of the new site are standard practice, confirming cGMP compliance, adequate quality systems, and genuine readiness for commercial production. Approval only follows once regulators are convinced the change introduces no additional risk to patients (2,5).

X. CASE STUDY: MANUFACTURING EXPANSION FOR BRENTUXIMAB VEDOTIN

Brentuximab vedotin is a CD30-targeted antibody-drug conjugate developed by Seagen (formerly Seattle Genetics) in collaboration with Takeda Pharmaceutical Company. It received U.S. FDA approval in 2011 for relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. As clinical use expanded after approval, global demand grew substantially, and

the sponsor needed to scale up manufacturing capacity to keep pace. To secure supply continuity, an additional facility was brought online to produce the drug-linker intermediate that connects the monoclonal antibody to the cytotoxic payload monomethyl auristatin E (MMAE). Because the drug-linker has such a direct influence on conjugation efficiency, stability, and overall quality, this site addition was treated as a major post-approval change and submitted to the FDA as a Prior Approval Supplement within an sBLA.

The submission included extensive analytical comparability work, examining structural characteristics, impurity and degradation profiles, residual solvent levels, and key physicochemical properties of drug-linker material from both the original and new facilities. The potential impact on the finished ADC was assessed too, through DAR distribution, aggregation levels, potency assays, and stability testing — none of which showed meaningful differences between the two sources.

Process validation batches were also manufactured at the new facility to confirm consistent commercial-scale performance. Approval followed a successful regulatory inspection that verified GMP compliance and appropriate containment controls for handling highly potent cytotoxic material. This case is a good illustration of how much weight thorough CMC documentation and comparability data carry when a sponsor seeks approval for a manufacturing site expansion in a complex biologic like an ADC.

XI. CONCLUSION

Adding a new drug-linker manufacturing site for an approved ADC is rarely simple, but it's often necessary to keep global supply reliable. Because the drug-linker plays such a central role in stability, safety, and therapeutic performance, regulators expect a rigorous case built on comprehensive CMC data, analytical comparability studies, process validation, and stability evidence. Approval only comes once a sponsor has convincingly shown that the change

won't compromise product quality or clinical performance.

What this review makes clear is that a successful sBLA submission depends on early planning, sound scientific justification, and close attention to regulatory expectations from the outset. As ADCs continue to gain ground in oncology, managing post-approval manufacturing changes efficiently will remain essential for keeping patients supplied without compromising quality or safety. Closer collaboration between sponsors and regulators, together with continued advances in analytical technology, should make these approvals faster and more predictable going forward.

REFERENCES

- [1] International Council for Harmonisation (ICH). Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Geneva: ICH; 2004.
- [2] U.S. Food and Drug Administration (FDA). Code of Federal Regulations Title 21, Part 601.12 — Changes to an Approved Application.
- [3] European Medicines Agency (EMA). Variations to Marketing Authorisations for Human Medicines. London: EMA.
- [4] Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody–drug conjugates. *Nat Rev Drug Discov.* 2017;16(5):315–337.
- [5] U.S. Food and Drug Administration (FDA). Process Validation: General Principles and Practices. Guidance for Industry. Silver Spring (MD): FDA; 2011.
- [6] International Council for Harmonisation (ICH). Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
- [7] European Medicines Agency (EMA). Guideline on Process Validation for Finished Products. London: EMA.
- [8] U.S. Food and Drug Administration (FDA). Changes to an Approved Application: Biological Products. Guidance for Industry. Silver Spring (MD): FDA; 1997.
- [9] Lambert JM, Morris CQ. Antibody–drug conjugates for personalized treatment of solid tumors. *Adv Ther.* 2017;34(5):1015–1035.

- [10] U.S. Food and Drug Administration (FDA).
Biologics License Applications (BLA) Process
(CBER).
- [11] International Council for Harmonisation (ICH).
Q7: Good Manufacturing Practice Guide for
Active Pharmaceutical Ingredients. Geneva: ICH;
2016.
- [12] U.S. Food and Drug Administration. Adcetris
(brentuximab vedotin) prescribing information.
Silver Spring (MD): FDA; 2011.